Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community EMA is re-examining Winlevi (clascoterone at lower concentration)

      in Treatment  8 upvotes 11 months ago
      Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

      community Breezula Phase 3 Results enough for maintenance?

      in Treatment  11 upvotes 1 month ago
      Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.

      community Pyrludimide (KX-826) or Breezula (clascoterone)

      in Treatment  9 upvotes 2 months ago
      The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

      community Fevipiprant 2019!

       15 upvotes 9 years ago
      The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.